Brazilin inhibits amyloid β-protein fibrillogenesis, remodels amyloid fibrils and reduces amyloid cytotoxicity

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Du, Wen Jie ^a   Guo, Jing Jing ^a   Gao, Ming Tao ^a   Hu, Sheng Quan ^c   Dong, Xiao Yan ^a,b   Han, Yi Fan ^c   Liu, Fu Feng ^a,b   Jiang, Shaoyi ^d   Sun, Yan ^a,b  

^a TIANJIN UNIVERSITY   (China)

^b Collaborative Innovation Center of Chemical Science and Engineering   (China)

^c HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^d University of Washington   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BENZOPYRAN DERIVATIVE; BRAZILIN; PROTEIN BINDING;

CHEMISTRY; CONFORMATION; HUMAN; METABOLISM; MOLECULAR MODEL; PROTEIN MULTIMERIZATION; PROTEINOSIS;

AMYLOID BETA-PEPTIDES; BENZOPYRANS; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN BINDING; PROTEIN MULTIMERIZATION;

EID: 84923072114     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07992     Document Type: Article

References (61)

1. Jakob-Roetne, R. & Jacobsen, H. Alzheimer's disease: from pathology to therapeutic approaches. Angew. Chem. Int. Edit. 48, 3030-3059 (2009).
2. Tinker-Mill, C., Mayes, J., Allsop, D. & Kolosov, O. V. Ultrasonic force microscopy for nanomechanical characterization of early and late-stage amyloid-beta peptide aggregation. Sci. Rep. 4, 4004 (2014).
3. Lesne, S. et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440, 352-357 (2006).
4. Shankar, G. M. et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842 (2008).
5. Choi, Y. J. et al. Neurotoxic amyloid beta oligomeric assemblies recreated in microfluidic platform with interstitial level of slow flow. Sci. Rep. 3, 1921 (2013).
6. Cohen, S. I. et al. Proliferation of amyloid-beta42 aggregates occurs through a secondary nucleation mechanism. P. Natl. Acad. Sci. U.S.A. 110, 9758-9763 (2013).
7. Meisl, G. et al. Differences in nucleation behavior underlie the contrasting aggregation kinetics of the A beta 40 and A beta 42 peptides. P. Natl. Acad. Sci. U.S.A. 111, 9384-9389 (2014).
8. Perrin, R.J., Fagan, A. M. & Holtzman, D.M. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461, 916-922 (2009).
9. Williams, P., Sorribas, A. & Howes, M. J. R. Natural products as a source of Alzheimer's drug leads. Nat. Prod. Rep. 28, 48-77 (2011).
10. Jiang, L. et al. Structure-based discovery of fiber-binding compounds that reduce the cytotoxicity of amyloid beta. Elife 2, e00857 (2013).
11. Sciarretta, K. L., Gordon, D. J. & Meredith, S. C. Peptide-based inhibitors of amyloid assembly. Method. Enzymol. 413, 273-312 (2006).
12. Hopping, G. et al. Designed alpha-sheet peptides inhibit amyloid formation by targeting toxic oligomers. Elife 3, e01681 (2014).
13. Morgado, I. et al. Molecular basis of beta-amyloid oligomer recognition with a conformational antibody fragment. P. Natl. Acad. Sci. U.S.A. 109, 12503-12508 (2012).
14. Miles, L.A., Crespi, G.A.N., Doughty, L. & Parker, M.W. Bapineuzumabcaptures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation. Sci. Rep. 3 (2013).
15. Zhang, M. et al. Nanomaterials for Reducing Amyloid Cytotoxicity. Adv. Mater. 25, 3780-3801 (2013).
16. Liu, T. & Bitan, G. Modulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanisms. ChemMedChem 7, 359-374 (2012).
17. Ehrnhoefer, D. E. et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Mol. Biol. 15, 558-566 (2008).
18. Ahmed, M. et al. Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Nat. Struct. Mol. Biol. 17, 561-567 (2010).
19. Chen, X., Yang, Y. & Zhang, Y. Isobavachalcone and bavachinin from Psoraleae Fructus modulate Abeta42 aggregation process through different mechanisms in vitro. FEBS Lett. 587, 2930-2935 (2013).
20. Wang, Q. et al. Tanshinones Inhibit Amyloid Aggregation by Amyloid-beta Peptide, Disaggregate Amyloid Fibrils, and Protect Cultured Cells. ACS Chem. Neurosci. 4, 1004-1015 (2013).
21. Rizzi, A. & Fioni, A. Virtual screening using PLS discriminant analysis and ROC curve approach: An application study on PDE4 inhibitors. J. Chem. Inf. Model. 48, 1686-1692 (2008).
22. Pajouhesh, H. & Lenz, G. R. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2, 541-553 (2005).
23. Jan, A., Hartley, D. M. & Lashuel, H. A. Preparation and characterization of toxic A beta aggregates for structural and functional studies in Alzheimer's disease research. Nat. Protoc. 5, 1186-1209 (2010).
24. Luhrs, T. et al. 3D structure of Alzheimer's amyloid-beta(1-42) fibrils. P. Natl. Acad. Sci. U.S.A. 102, 17342-17347 (2005).
25. Pellarin, R. & Caflisch, A. Interpreting the aggregation kinetics of amyloid peptides. J. Mol. Biol. 360, 882-892 (2006).
26. Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489 (2003).
27. Agholme, L. et al. An In Vitro Model for Neuroscience: Differentiation of SH-SY5Y Cells into Cells with Morphological and Biochemical Characteristics of Mature Neurons. J. Alzheimers. Dis. 20, 1069-1082 (2010).
28. Bieschke, J. et al. Small-molecule conversion of toxic oligomers to nontoxic beta-sheet-rich amyloid fibrils. Nat. Chem. Biol. 8, 93-101 (2012).
29. Petkova, A. T., Yau, W. M. & Tycko, R. Experimental constraints on quaternary structure in Alzheimer's beta-amyloid fibrils. Biochemistry 45, 498-512 (2006).
30. Lu, J. X. et al. Molecular structure of beta-amyloid fibrils in Alzheimer's disease brain tissue. Cell 154, 1257-1268 (2013).
31. Yu, L. P. et al. Structural Characterization of a Soluble Amyloid beta-Peptide Oligomer. Biochemistry 48, 1870-1877 (2009).
32. Pham, J. D., Spencer, R. K., Chen, K. H. & Nowick, J. S. A Fibril-Like Assembly of Oligomers of a Peptide Derived from beta-Amyloid. J. Am. Chem. Soc. 136, 12682-12690 (2014).
33. Kassler, K., Horn, A. H. C. & Sticht, H. Effect of pathogenic mutations on the structure and dynamics of Alzheimer's A beta(42)-amyloid oligomers. J. Mol. Model. 16, 1011-1020 (2010).
34. Hochdorffer, K. et al. Rational design of beta-sheet ligands against Abeta42-induced toxicity. J. Am. Chem. Soc. 133, 4348-4358 (2011).
35. Yu, X. et al. Molecular interactions of Alzheimer amyloid-beta oligomers with neutral and negatively charged lipid bilayers. Phys. Chem. Chem. Phys. 15, 8878-8889 (2013).
36. Blinov, N., Dorosh, L., Wishart, D. &Kovalenko, A. Association Thermodynamics and Conformational Stability of beta-Sheet Amyloid beta(17-42) Oligomers: Effects of E22Q (Dutch) Mutation and Charge Neutralization. Biophys. J. 98, 282-296 (2010).
37. Ono, K., Hasegawa, K., Naiki, H. & Yamada, M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J. Neurosci. Res. 75, 742-750 (2004).
38. Auer, S., Ricchiuto, P. & Kashchiev, D. Two-Step Nucleation of Amyloid Fibrils: Omnipresent or Not? J. Mol. Biol. 422, 723-730 (2012).
39. Bae, I. K. et al. Suppression of lipopolysaccharide-induced expression of inducible nitric oxide synthase by brazilin in RAW 264.7 macrophage cells. Eur. J. Pharmacol. 513, 237-242 (2005).
40. Hwang, G. S. et al. Effects of Brazilin on the phospholipase A2 activity and changes of intracellular free calcium concentration in rat platelets. Arch. Pharm. Res. 21, 774-778 (1998).
41. Shytle, R. D. et al. Optimized turmeric extracts have potent anti-amyloidogenic effects. Curr. Alzheimer. Res. 6, 564-571 (2009).
42. Lu, C. J. et al. Design, Synthesis, and Evaluation of Multitarget-Directed Resveratrol Derivatives for the Treatment of Alzheimer's Disease. J. Med. Chem. 56, 5843-5859 (2013).
43. Marshall, K. E. et al. Hydrophobic, aromatic, and electrostatic interactions play a central role in amyloid fibril formation and stability. Biochemistry 50, 2061-2071 (2011).
44. Attanasio, F. et al. Carnosine Inhibits A beta 42 Aggregation by Perturbing the H-Bond Network inand around the Central Hydrophobic Cluster. Chembiochem 14, 583-592 (2013).
45. McLaurin, J. et al. Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit A beta-induced toxicity. J. Biol. Chem. 275, 18495-18502 (2000).
46. Yang, D. S. et al. Manipulating the amyloid-beta aggregation pathway with chemical chaperones. J. Biol. Chem. 274, 32970-32974 (1999).
47. Ladiwala, A. R. A. et al. Resveratrol Selectively Remodels Soluble Oligomers and Fibrils of Amyloid A beta into Off-pathway Conformers. J. Biol. Chem. 285, 24228-24237 (2010).
48. Bieschke, J. et al. EGCG remodels mature alpha-synuclein and amyloid-beta fibrils and reduces cellular toxicity. P. Natl. Acad. Sci. U.S.A. 107, 7710-7715 (2010).
49. Palhano, F. L., Lee, J., Grimster, N. P. & Kelly, J. W. Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils. J. Am. Chem. Soc. 135, 7503-7510 (2013).
50. Jeong, J. S. et al. Novel mechanistic insight into the molecular basis of amyloid polymorphism and secondary nucleation during amyloid formation. J. Mol. Biol. 425, 1765-1781 (2013).
51. Deng, Z. et al. A validated LC-MS/MS method for rapid determination of brazilin in rat plasma and its application to a pharmacokinetic study. Biomed. Chromatogr. 27, 802-806 (2013).
52. Jia, Y. Y. et al. Application of a liquid chromatography-tandem mass spectrometry method to the pharmacokinetics, tissue distribution and excretion studies of brazilin in rats. J. Chromatogr. B 931, 61-67 (2013).
53. Jia, Y. Y. et al. A simple high-performance liquid chromatographic method for the determination of brazilin and its application to a pharmacokinetic study in rats. J. Ethnopharmacol. 151, 108-113 (2014).
54. Wang, Q. et al. Structural, morphological, and kinetic studies of beta-amyloid peptide aggregation on self-assembled monolayers. Phys. Chem. Chem. Phys. 13, 15200-15210 (2011).
55. Hu, S. Q. et al. Bis(propyl)-cognitin protects against glutamate-induced neuro-excitotoxicity via concurrent regulation of NO, MAPK/ERK and PI3-K/Akt/GSK3 beta pathways. Neurochem. Int. 62, 468-477 (2013).
56. Van Gunsteren, W. F., Billeter, S. R., Eising, A. A., Hünenberger, P. H., Krüger, P., Mark, A. E., Scott, W. R. P. & Tironi, I. G. Biomolecular Simulation: The GROMOS96 Manual and User Guide [vdf Hochschulverlag AG (ed.)] [1-1044] (Zürich, Switzerland, 1996).
57. Darden, T., York, D. & Pedersen, L. Particle Mesh Ewald-an N.Log(N) Method for Ewald Sums in Large Systems. J. Chem. Phys. 98, 10089-10092 (1993).
58. Bussi, G., Donadio, D. & Parrinello, M. Canonical sampling through velocity rescaling. J. Chem. Phys. 126, 014101 (2007).
59. Berendsen, H. J. C. et al. Molecular-Dynamics with Coupling to an External Bath. J. Chem. Phys. 81, 3684-3690 (1984).
60. Hess, B., Bekker, H., Berendsen, H. J. C. & Fraaije, J. G. E. M. LINCS: A linear constraint solver for molecular simulations. J. Comput. Chem. 18, 1463-1472 (1997).
61. Humphrey, W., Dalke, A. & Schulten, K. VMD: Visual molecular dynamics. J. Mol. Graph. Model. 14, 33-38 (1996).